Allogeneic Mesenchymal Stem Cell-Based Treatment Legislation in Latin America: The Need for Standardization in a Medical Tourism Context

Orozco-Solares, Tanya Estefanía; León-Moreno, Lilia Carolina; Rojas-Rizo, Andrea; Manguart-Paez, Karen; Caplan, Arnold I.

doi:10.1089/scd.2022.0013

Cited by 4 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is four times higher than that of five years ago [ 45 ]. Another very similar problem is so-called medical tourism, which consists of people usually going abroad to underdeveloped countries in search of treatments that are not approved or are even banned in their country [ 53 ]. Most of these clinics offer treatments for multiple diseases for which MSCs have not been approved yet, such as autism spectrum disorders, alopecia, anti-aging therapies, chronic pain, erectile dysfunction, and even coronavirus disease 2019 (COVID-19) [ 54 ].…”

Section: Current Issues and Future Directionsmentioning

confidence: 99%

Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World

Fernández-Garza,

Barrera-Barrera,

Barrera-Saldaña

2023

Pharmaceuticals

View full text Add to dashboard Cite

Cellular therapy has used mesenchymal stem cells (MSCs), which in cell culture are multipotent progenitors capable of producing a variety of cells limited to the mesoderm layer. There are two types of MSC sources: (1) adult MSCs, which are obtained from bone marrow, adipose tissue, peripheral blood, and dental pulp; and (2) neonatal-tissue-derived MSCs, obtained from extra-embryonic tissues such as the placenta, amnion, and umbilical cord. Until April 2023, 1120 registered clinical trials had been using MSC therapies worldwide, but there are only 12 MSC therapies that have been approved by regulatory agencies for commercialization. Nine of the twelve MSC-approved products are from Asia, with Republic of Korea being the country with the most approved therapies. In the future, MSCs will play an important role in the treatment of many diseases. However, there are many issues to deal with before their application and usage in the medical field. Some strategies have been proposed to face these problems with the hope of reaching the objective of applying these MSC therapies at optimal therapeutic levels.

show abstract

Section: Current Issues and Future Directionsmentioning

confidence: 99%

Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World

Fernández-Garza,

Barrera-Barrera,

Barrera-Saldaña

2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…This was four times more than five years ago [35]. Another very similar concern is the so-called medical tourism, which consists of the same situation where people fo to foreign countries, mostly underdeveloped countries, in search of treatments that are not approved or even prohibited in their country [36]. Most of these clinics offer treatments for multiple diseases for which MSCs have not been approved yet, such as autism spectrum disorders, alopecia, anti-aging therapies, chronic pain, erectile dysfunction, and even Coronavirus Disease 2019 (COVID-19) [37].…”

Section: Current Issues and Future Directionsmentioning

confidence: 99%

Mesenchymal Stem Cells Therapies Approved by Regulatory Agencies Around the World

Fernández-Garza¹,

Barrera-Barrera²,

Barrera-Saldaña³

2023

Preprint

View full text Add to dashboard Cite

Cell therapy has used mesenchymal stem cells (MSCs) which in cell culture are multipotent progenitors, capable of producing a variety of cells limited to the mesoderm layer. There are two types of MSCs sources: 1) adult MSCs, which are obtained from the bone marrow, adipose tissue, peripheral blood, and dental pulp; and 2) neonatal tissue-derived MSCs, obtained from extra-embryonic tissues such as the placenta, amnion, and umbilical cord. Until April 2023, there are 1,120 registered clinical trials using MSCs therapies worldwide, but there are only 12 MSCs therapies that have been approved by regulatory agencies for commercialization. Nine of the twelve approved MSCs products are from Asia, with South Korea being the country with the most approved therapies. In the future, MSCs will play an important role in the treatment of many diseases. However, there are many issues to deal with before their application and usage in medical practice. Some strategies have been proposed to face these problems with the hope of reaching the objective of applying these MSCs therapies at optimal therapeutic levels.

show abstract

Current progress and limitations of research regarding the therapeutic use of adipose-derived stem cells: literature review

Skrypnyk

2024

J.Umm Al-Qura Univ. Appll. Sci.

View full text Add to dashboard Cite

Background Adipose tissue has recently become one of the most promising and predominant sources of mesenchymal stem cells owing to its high accessibility, culturing properties, regenerative potential, and relatively fewer ethical considerations. From the time of the adipose-derived stem cells (ADSCs) discovery, many beneficial properties have been found, including their regenerative, anti-inflammatory, immunomodulatory, and antimicrobial effects. The number of publications and clinical trials using ADSCs has increased significantly worldwide, attesting to the promising nature of the therapeutic properties of ADSCs. Main body of the abstract In clinical studies, ADSCs are mainly used to treat wounds, multiple sclerosis, soft tissue trauma, aging, diabetes, Parkinson’s disease, bone and cartilage regeneration, strokes, and spinal cord injuries. Few and insignificant adverse effects after ADSC treatment have been documented, suggesting their relative safety for clinical use. Despite significant progress in ADSC-related studies, several issues are yet to be addressed, including a lack of standardization of ADSC-associated protocols and the methods used to obtain them, inconsistent dosages, small numbers of patients in each treatment group, and variable graft purity. This severely complicates our ability to compare these studies, making the results even of similar studies controversial. Short conclusion This review described the current stage of ADSCs-based treatment outcomes and their limitations, associated with standardization of ADSCs.

show abstract

Allogeneic Mesenchymal Stem Cell-Based Treatment Legislation in Latin America: The Need for Standardization in a Medical Tourism Context

Cited by 4 publications

References 51 publications

Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World

Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World

Mesenchymal Stem Cells Therapies Approved by Regulatory Agencies Around the World

Current progress and limitations of research regarding the therapeutic use of adipose-derived stem cells: literature review

Contact Info

Product

Resources

About